GlassScriptPhysician profile
Vipul Pandya
NPI 1225064033
$2,150.13
in general payments reported to CMS, 2019-2025
21 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $376 · 2021: $580 · 2022: $239 · 2023: $297 · 2024: $105 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $421.58 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $292.59 | 2023-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $247.30 | 2020-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $178.54 | 2020-2025 | Lokelma, Farxiga |
| Medtronic Vascular, INC. | $163.09 | 2020 | |
| Amarin Pharma, INC. | $162.40 | 2019-2021 | |
| Pfizer INC. | $148.23 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $79.38 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $77.16 | 2019-2023 | Xarelto |
| Abbott Laboratories | $54.91 | 2019-2021 | |
| Philips North America LLC | $43.19 | 2020-2022 | |
| Novo Nordisk INC | $32.39 | 2021 | |
| Preventice Services, LLC | $32.05 | 2020 | |
| Sanofi-Aventis U.S. LLC | $27.02 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $19.45 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.40 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $19.34 | 2021 | |
| Edwards Lifesciences Corporation | $18.82 | 2019 | |
| Bridgebio Pharma, INC. | $16.61 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $14.34 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipul Pandya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.